CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology, including HemoDefend, ContrastSorb, DrugSorb, BetaSorb and others.
|Headquarters||7 Deerpark Dr Ste K|
MONMOUTH JUNCTION, NJ, United States 08852-1921
|Chairman of the Board||Al Kraus|
|President, Chief Executive Officer, Director||Phillip Chan|
|Chief Financial Officer||Kathleen Bloch|
|Chief Operating Officer||Vincent Capponi|
|Chief Medical Officer||Robert Bartlett|
|Shares Out.||25.4M||Book Value||$0.32|
|Annual Dividend Rate||0.00 USD||Price/Sales (TTM)||19.4|
|Ex-Div Date||1/1/01||P/Cash Flow (TTM)||--|
|Pay Date||1/1/01||Operating Margin||-134.38%|
*GAAP = prior to non-GAAP analyst adjusted earnings.